Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
JANX Janux Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: JANX
Price (delayed)
$25.56
Market cap
$1.51B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.35
Enterprise value
$1.46B
Highlights
JANX's equity has surged by 54% year-on-year
Janux Therapeutics's debt has decreased by 7% YoY
JANX's gross profit is up by 28% YoY but it is down by 12% QoQ
The revenue has grown by 28% YoY but it has contracted by 12% from the previous quarter
The net income has contracted by 40% YoY and by 13% from the previous quarter
The EPS has contracted by 12% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of JANX
Market
Valuations
Earnings
Shares outstanding
59.18M
Market cap
$1.51B
Enterprise value
$1.46B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
169.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
156.44
Revenue
$9.34M
Gross profit
$9.34M
Operating income
-$113.58M
Net income
-$77.74M
EBIT
-$77.74M
EBITDA
-$75.7M
Free cash flow
-$46.53M
Per share
Balance sheet
Liquidity
EPS
-$1.35
EPS diluted
-$1.35
Free cash flow per share
-$0.75
Book value per share
$17.13
Revenue per share
$0.15
TBVPS
$17.01
Total assets
$1.05B
Total liabilities
$38.3M
Debt
$22.61M
Equity
$1.01B
Working capital
$1.01B
Debt to equity
0.02
Current ratio
58.47
Quick ratio
57.99
Net debt/EBITDA
0.69
Margins
Efficiency
Dividend
EBITDA margin
-810.8%
Gross margin
100%
Net margin
-832.7%
Operating margin
-1,216.6%
Return on assets
-8.9%
Return on equity
-9.3%
Return on invested capital
-10.4%
Return on capital employed
-7.5%
Return on sales
-832.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JANX stock price
How has the Janux Therapeutics stock price performed over time
Intraday
-3.07%
1 week
-22.26%
1 month
-4.73%
1 year
-50.79%
YTD
-52.26%
QTD
-5.33%
Financial performance
How have Janux Therapeutics's revenue and profit performed over time
Revenue
$9.34M
Gross profit
$9.34M
Operating income
-$113.58M
Net income
-$77.74M
Gross margin
100%
Net margin
-832.7%
JANX's operating income has dropped by 56% year-on-year and by 15% since the previous quarter
The net income has contracted by 40% YoY and by 13% from the previous quarter
The operating margin has contracted by 30% from the previous quarter and by 22% YoY
JANX's gross profit is up by 28% YoY but it is down by 12% QoQ
Price vs fundamentals
How does JANX's price correlate with its fundamentals
Growth
What is Janux Therapeutics's growth rate over time
Valuation
What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
1.49
P/S
169.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
156.44
The EPS has contracted by 12% YoY and by 5% from the previous quarter
JANX's equity has surged by 54% year-on-year
JANX's P/B is 47% below its last 4 quarters average of 2.8 and 29% below its 5-year quarterly average of 2.1
The revenue has grown by 28% YoY but it has contracted by 12% from the previous quarter
The P/S is 15% less than the last 4 quarters average of 197.9 but 9% more than the 5-year quarterly average of 154.5
Efficiency
How efficient is Janux Therapeutics business performance
JANX's return on equity is up by 31% year-on-year
The ROA has grown by 28% YoY
The ROS has contracted by 28% from the previous quarter and by 9% YoY
The return on invested capital is up by 27% year-on-year and by 6% since the previous quarter
Dividends
What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JANX.
Financial health
How did Janux Therapeutics financials performed over time
Janux Therapeutics's total assets has surged by 53% YoY
The total liabilities has grown by 15% YoY
Janux Therapeutics's debt is 98% lower than its equity
JANX's equity has surged by 54% year-on-year
Janux Therapeutics's debt to equity has plunged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.